Dr. Hamstra on Length of Radiation Treatments for Patients With Prostate Cancer

Video

Daniel A. Hamstra, MD, PhD, assistant professor of Radiation Oncology, University of Michigan Health System, discusses clinical trials comparing the length of radiation treatments for patients with prostate cancer.

Daniel A. Hamstra, MD, PhD, assistant professor of Radiation Oncology, University of Michigan Health System, discusses clinical trials comparing different lengths of radiation treatments for patients with prostate cancer.

The RTOG 0145 study compared an 8-week to 5.5-week regimen of radiation therapy in more than 1000 patients with prostate cancer, Hamstra explains. Outcomes were found to be identical regarding tumor recurrence and short- and long-term side effects, with a small increase in gastrointestinal-related effects in the longer regimen.

In the CHIP trial, more than 3000 patients from the United Kingdom were randomized to receive either an 8-week regimen, 19 treatments, or 20 treatments. In the 20-treatment arm, outcomes were reported to be similar in comparison to the 8-week regimen arm.

<<<

View more from the 2016 GU Cancer Symposium

Related Videos
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Carmen Guerra, MD, MSCE, FACP
Kara N. Maxwell, MD, PhD
Josep Maria Piulats Rodriguez, MD, PhD
Phillip J. Koo, MD
Phillip J. Koo, MD
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.
Eric S. Christenson, MD
Samer A. Srour, MB ChB, MS
Rebecca L. Porter, MD, PhD